RxDoctor Payments Data

Benjamin Thomas

Podiatrist · Providence, UTNPI 1043659055

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,637 of the $2,332 with a category attached, or 70.2%. 33 manufacturers reported payments, led by Paragon 28, Inc. at 33.7% of the total. 2025 is the largest year on record at $1,011, 3.1 times the $322 reported in 2019.

$2,332in general payments, 2019–2025

Across 86 payments — averaging $27.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paragon 28, Inc.$787
  • Anika Therapeutics, Inc.$164
  • Zyla Life Sciences, Inc.$160
  • Averitas Pharma Inc.$150
  • Amgen$115
  • Boehringer Ingelheim$92
  • plus $865 from 27 others

What the payments were for

  • Travel & lodging$69530%
  • Food & beverage$1,63770%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,332 in reported general payments places this provider in the 65th percentile of 59 podiatrist providers in Utah.

See all podiatrist providers in Utah

Medicare billing

Part B allowed, 2024
$184,666
Medicare patients
275
Services billed
4,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Terbinafine Hcl16$168
Cephalexin12$158

Paid to pharmacies, not to this prescriber.

Other podiatrist in Providence

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →